Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.04 -1.29 (-5.11%)
Streaming Delayed Price Updated: 3:57 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
Via Investor Brand Network
News headline image
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Pricing of Underwritten Offering
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.